Belite Bio, Inc
Belite Bio, Inc (BLTE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BLTE · as of Sep 30, 2025
Ownership Breakdown
34
Institutional Holders
▲ 16 vs Q2
$169.35M
Total Inst. Value
▲ $164.84M vs Q2
40.09M
Shares Outstanding
freeFloat 46.11%
2.29M
13F Shares Held
▲ 2.21M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BLTE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 875.0K | 2.69% | 2.69% | $64.75B | Nov 14, 2025 | NEW |
RTW INVESTMENTS, LP pharmaceutical preparations | 312.5K | 95.90% | 95.90% | $23.13B | Nov 14, 2025 | NEW |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 312.5K | 95.90% | 95.90% | $23.13B | Nov 14, 2025 | NEW |
SOLEUS CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 210.0K | 64.45% | 64.45% | $15.54B | Nov 14, 2025 | NEW |
EVENTIDE ASSET MANAGEMENT, LLC pharmaceutical preparations | 195.3K | 59.94% | 59.94% | $14.45B | Nov 14, 2025 | NEW |
MARSHALL WACE, LLP pharmaceutical preparations | 187.5K | 57.54% | 57.54% | $13.88B | Nov 13, 2025 | ▲ 178.0K |
PERCEPTIVE ADVISORS LLC pharmaceutical preparations | 49.8K | 15.28% | 15.28% | $3.68B | Nov 14, 2025 | NEW |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 20.7K | 6.37% | 6.37% | $1.53B | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 15.6K | 4.80% | 4.80% | $1.16B | Nov 12, 2025 | ▲ 2.8K |
STATE STREET CORP pharmaceutical preparations | 13.3K | 4.07% | 4.07% | $982.20M | Nov 14, 2025 | ▼ 6.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+220.5K shares14
New Positions
first time holders5
Decreased
−9.4K shares0
Sold Out
fully exitedNet shares change (top 50)
+211.1K
+220.5K / −9.4K
Net new holders
+23
14 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BLTE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
112
Sell transactions
0.03
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
MATA NATHAN L. Chief Scientific Officer | May 7, 2026 | Sale | 226 | $152.45 | $34.5K | 440 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 7, 2026 | Sale | 428 | $153.56 | $65.7K | 12 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 7, 2026 | Sale | 3 | $154.61 | $463.83 | 9 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 7, 2026 | Sale | 9 | $155.25 | $1.4K | 0 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 8 | $151.57 | $1.2K | 1.7K | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 424 | $152.67 | $64.7K | 1.2K | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 128 | $153.42 | $19.6K | 1.1K | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 240 | $154.41 | $37.1K | 866 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 100 | $155.97 | $15.6K | 766 | Form 4 ↗ |
MATA NATHAN L. Chief Scientific Officer | May 6, 2026 | Sale | 100 | $156.00 | $15.6K | 666 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Belite Bio, Inc (BLTE) is primarily owned by institutional investors, who hold approximately 5.7% of total shares outstanding. Company insiders own approximately 53.89%, while retail and public investors account for the remaining 40.40%.
The largest institutional shareholder of Belite Bio, Inc is RA CAPITAL MANAGEMENT, L.P., holding approximately 875,000 shares — equal to 2.69% of outstanding shares — as of September 30, 2025.
A total of 34 institutional investors currently hold BLTE stock, with a combined institutional value of approximately $169,346,585 as of the most recent 13F filing period.
Frequently asked questions
BLTE ownershipBelite Bio, Inc (BLTE) is primarily owned by institutional investors, who hold approximately 5.7% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 2.69% stake. Company insiders hold 53.89%. Data sourced from SEC Form 13F as of September 30, 2025.